Carlo Brugnara, MD
|Hospital Title||Senior Associate|
|Academic Title||Professor of Pathology|
300 Longwood Avenue
Boston MA 02115
Carlo Brugnara's research is focused on regulation of cell volume and transport of ions across the cell membrane. His studies have described the role of specific transport proteins in inducing erythrocyte dehydration in sickle cell disease. His work has suggested several new potential therapeutic approaches for sickle cell disease, including an ion channel blocker (ICA-17043), oral Mg supplements (Mg-pidolate), inhaled nitric oxide (NO).
About Carlo Brugnara
Carlo Brugnara received his MD degree from the University of Padua, Italy.?He completed an internship at University of Verona Hospital, a residency at Brigham and Women's Hospital, and fellowships at Harvard Medical School and Brigham and Women's Hospital.
- Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickle redblood cell dehydration in vitro and in vivo in SAD mice. Blood 2003; 101:2412-2418.
- Weiner DL, Hibberd P, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. Journal of the American Medical Association. 2003; 289: 1136-1142.
- Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clinical Chemistry 2003; 49: 1573-1578.